Travis Dumont1, Anand Rughani, Jeremy Silver, Bruce I Tranmer. 1. Division of Neurosurgery, Department of Surgery, University of Vermont, 111 Colchester Ave, Fletcher 5, Burlington, VT 05401, USA. travis.dumont@vtmednet.org
Abstract
OBJECTIVE: Symptomatic cerebral vasospasm (SCV) is a morbid sequela of subarachnoid hemorrhage (SAH). Its etiology is multifactorial and predicting onset can be challenging. Diabetes mellitus (DM) is known to affect vasoactive properties of vessels, but it has not been definitively correlated with SCV. We report that pre-existing DM is independently and strongly correlated with SCV, despite intensive glycemic control. METHODS: This is a retrospective chart review of all patients with aneurysmal subarachnoid hemorrhage (aSAH) admitted to a single academic medical center between January 2002 and January 2008 (n = 145). Patients presenting greater than 14 days after ictus, as well as those not surviving the first 3 days post-ictus were excluded from analysis. Remaining patients (n = 113) were assessed for study parameters including pre-existing DM, mean daily blood glucose, and additional known correlates to SCV. Multivariate analysis was performed to assess risk factors for SCV development. The primary outcome measure was SCV, defined as neurological change in conjunction with evidence of vessel spasm by either angiography or transcranial ultrasound. RESULTS: Of 113 patients included in the study, 42 (37%) had SCV. Patients with DM (80% incidence of SCV) had an increased risk of subsequently developing SCV (OR 9.90, P = 0.031). Elevated blood glucose was not associated with increased risk of vasospasm and no difference in glycemic control was noted between patients with or without DM. SCV resulted in worsened mortality and Glasgow Outcome Score for survivors (P < 0.005). CONCLUSION: In this group of patients with SAH, diabetes mellitus is identified as a risk factor for development of SCV. Blood glucose management during hospitalization was similar in diabetics and non-diabetics, suggesting that the longstanding effects of microvascular disease may be more relevant in the development of SCV then acute glycemic control in these patients.
OBJECTIVE: Symptomatic cerebral vasospasm (SCV) is a morbid sequela of subarachnoid hemorrhage (SAH). Its etiology is multifactorial and predicting onset can be challenging. Diabetes mellitus (DM) is known to affect vasoactive properties of vessels, but it has not been definitively correlated with SCV. We report that pre-existing DM is independently and strongly correlated with SCV, despite intensive glycemic control. METHODS: This is a retrospective chart review of all patients with aneurysmal subarachnoid hemorrhage (aSAH) admitted to a single academic medical center between January 2002 and January 2008 (n = 145). Patients presenting greater than 14 days after ictus, as well as those not surviving the first 3 days post-ictus were excluded from analysis. Remaining patients (n = 113) were assessed for study parameters including pre-existing DM, mean daily blood glucose, and additional known correlates to SCV. Multivariate analysis was performed to assess risk factors for SCV development. The primary outcome measure was SCV, defined as neurological change in conjunction with evidence of vessel spasm by either angiography or transcranial ultrasound. RESULTS: Of 113 patients included in the study, 42 (37%) had SCV. Patients with DM (80% incidence of SCV) had an increased risk of subsequently developing SCV (OR 9.90, P = 0.031). Elevated blood glucose was not associated with increased risk of vasospasm and no difference in glycemic control was noted between patients with or without DM. SCV resulted in worsened mortality and Glasgow Outcome Score for survivors (P < 0.005). CONCLUSION: In this group of patients with SAH, diabetes mellitus is identified as a risk factor for development of SCV. Blood glucose management during hospitalization was similar in diabetics and non-diabetics, suggesting that the longstanding effects of microvascular disease may be more relevant in the development of SCV then acute glycemic control in these patients.
Authors: Neeraj Badjatia; Mehmet A Topcuoglu; Ferdinando S Buonanno; Eric E Smith; Raul G Nogueira; Guy A Rordorf; Bob S Carter; Christopher S Ogilvy; Aneesh B Singhal Journal: Crit Care Med Date: 2005-07 Impact factor: 7.598
Authors: Jean G de Oliveira; Jürgen Beck; Christian Ulrich; Julian Rathert; Andreas Raabe; Volker Seifert Journal: Neurosurg Rev Date: 2006-10-24 Impact factor: 3.042
Authors: Alejandro A Rabinstein; Mark A Pichelmann; Jonathan A Friedman; David G Piepgras; Douglas A Nichols; Jon I McIver; L Gerard Toussaint; Robyn L McClelland; Jimmy R Fulgham; Fredric B Meyer; John L D Atkinson; Eelco F Wijdicks Journal: J Neurosurg Date: 2003-02 Impact factor: 5.115
Authors: Matthew J McGirt; Robert Blessing; Michael J Alexander; Shahid M Nimjee; Graeme F Woodworth; Allan H Friedman; Carmelo Graffagnino; Daniel T Laskowitz; John R Lynch Journal: J Neurosurg Date: 2006-11 Impact factor: 5.115
Authors: Aaron S Dumont; Randall J Dumont; Michael M Chow; Chi-Lung Lin; Tarkan Calisaneller; Klaus F Ley; Neal F Kassell; Kevin S Lee Journal: Neurosurgery Date: 2003-07 Impact factor: 4.654
Authors: Adam Institoris; James A Snipes; Prasad V Katakam; Ferenc Domoki; Krisztina Boda; Ferenc Bari; David W Busija Journal: Am J Physiol Heart Circ Physiol Date: 2011-03-18 Impact factor: 4.733
Authors: Nyika D Kruyt; Geert Jan Biessels; J Hans DeVries; Merel J A Luitse; Marinus Vermeulen; Gabriel J E Rinkel; W Peter Vandertop; Yvo B Roos Journal: J Cereb Blood Flow Metab Date: 2010-07-14 Impact factor: 6.200
Authors: Luís Guilherme Bastos Silva Aguiar Coelho; José Manuel Dias Costa; Elsa Irene Peixoto Azevedo Silva Journal: Rev Bras Ter Intensiva Date: 2016-06
Authors: Wessel E van der Steen; Eva L Leemans; René van den Berg; Yvo B W E M Roos; Henk A Marquering; Dagmar Verbaan; Charles B L M Majoie Journal: Neuroradiology Date: 2019-01-28 Impact factor: 2.804
Authors: Brandon P Lucke-Wold; Aric F Logsdon; Branavan Manoranjan; Ryan C Turner; Evan McConnell; George Edward Vates; Jason D Huber; Charles L Rosen; J Marc Simard Journal: Int J Mol Sci Date: 2016-04-02 Impact factor: 5.923